Abiomed at CRT 2023: Benefits of Impella-Supported High Risk PCI and Impella Innovation

Featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failure

Related Keywords

Washington ,United States ,Johnson Medtech ,William Oneill ,Navin Kapur ,Arsalan Abu ,Cardiovascular Research Technologies ,Abiomed ,Abiomed Technology ,Drug Administration ,Abiomed Inc ,Cardiovascular Research Foundation ,Power Break ,Olive Cases ,Arsalan Abu Much ,Kent Theater ,High Risk ,High Reward ,Modern Impella Utilization ,Technology Highlights ,Low Profile Sheath ,Impella Content ,Tufts Uses ,Hemodynamic Support Algorithm ,Determine What Devices ,Trial May Change ,Hemodynamic Support Protocols ,Henry Ford Hospital ,Williamo Neill ,